Novozymes Financials
| NVZMY Stock | USD 59.38 1.92 3.34% |
Novozymes |
Understanding current and past Novozymes Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Novozymes' financial statements are interrelated, with each one affecting the others. For example, an increase in Novozymes' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Novozymes' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novozymes AS. Check Novozymes' Beneish M Score to see the likelihood of Novozymes' management manipulating its earnings.
Novozymes Stock Summary
Novozymes competes with Air Liquide, PPG Industries, Sherwin Williams, Air Products, and Sika AG. Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US6701081092 |
| Business Address | Krogshoejvej 36, Bagsvaerd, |
| Sector | Basic Materials |
| Industry | Specialty Chemicals |
| Benchmark | Dow Jones Industrial |
| Website | www.novozymes.com |
| Phone | 45 44 46 00 00 |
| Currency | USD - US Dollar |
Novozymes Key Financial Ratios
Novozymes' financial ratios allow both analysts and investors to convert raw data from Novozymes' financial statements into concise, actionable information that can be used to evaluate the performance of Novozymes over time and compare it to other companies across industries.| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Target Price | 51.26 | |||
| Beta | 0.4 | |||
| Z Score | 0.6 |
Novozymes Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novozymes's current stock value. Our valuation model uses many indicators to compare Novozymes value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novozymes competition to find correlations between indicators driving Novozymes's intrinsic value. More Info.Novozymes AS is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.38 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novozymes AS is roughly 2.63 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novozymes by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novozymes' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Novozymes AS Systematic Risk
Novozymes' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novozymes volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Novozymes AS correlated with the market. If Beta is less than 0 Novozymes generally moves in the opposite direction as compared to the market. If Novozymes Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novozymes AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novozymes is generally in the same direction as the market. If Beta > 1 Novozymes moves generally in the same direction as, but more than the movement of the benchmark.
Novozymes November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Novozymes help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novozymes AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novozymes AS based on widely used predictive technical indicators. In general, we focus on analyzing Novozymes Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novozymes's daily price indicators and compare them against related drivers.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 8.24 | |||
| Value At Risk | (2.21) | |||
| Potential Upside | 2.22 |
Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.